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Abstract. Matrix metalloproteinases (MMPs) and 
their tissue inhibitors (TIMPs) play a complex role in 
the pathogenesis of atherosclerosis. We compared (1) 
the histopathological findings in patients with abdom-
inal aortic aneurysms (AAA) and aortoiliac occlusive 
disease (AOD); (2) the expression of MMP-2/MMP-9 
and TIMP-1/TIMP-2 in aortic layers, inflammatory 
cells and smooth muscle cells (SMCs), aiming to 
identify the common underlying pathogenic mecha-
nisms of the disease development. Samples were ob-
tained from 30 patients with AAA and 30 with AOD. 
Aortic histology and immunohistochemistry were 
performed to evaluate inflammatory changes and 
MMP and TIMP expression. Thrombosis and ulcera-
tion were more frequent in AOD than in AAA. The 
MMP-9 expression was elevated in all aortic layers 
of AAA patients and in media/adventitia of AOD pa-
tients, mainly followed by lower expression of its in-
hibitor TIMP-1. Higher MMP-9 expression was also 
found in SMCs and macrophages of both AAA and 
AOD specimens, while higher TIMP-1/TIMP-2 were 
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predominantly observed in the lymphocytes and 
macrophages of the aneurysm. These results showed 
that both conditions exhibited increased MMP-9 ex-
pression; however, the MMP expression pattern dif-
fered to some degree between the aneurysms and 
occlusive disease. The variations in molecular mech-
anisms underlying dilatative/stenosing disease war-
rant further investigation.
Introduction
Matrix metalloproteinases (MMPs) are a family of 
zinc-dependent endopeptidases that are implicated in a 
variety of physiological processes such as embryonic 
development, morphogenesis, apoptosis and tissue re-
modelling. Based on the substrate specificity, MMPs are 
divided into subclasses such as gelatinases, elastases, 
and collagenases. They are inhibited by specific tissue 
inhibitors of metalloproteinases (TIMPs). The imbal-
ance between MMPs and their TIMPs has been shown 
to contribute to different pathologies such as cancer, 
rheumatoid arthritis and aneurysm formation (Aziz and 
Kuivaniemi, 2007). MMP-2 and MMP-9 degrade dena-
tured fibrillar collagen (gelatin), elastin, and native IV, 
V, and VII collagen along with other extracellular ma-
trix (ECM) components. MMP-2 is constitutively ex-
pressed in SMCs and fibroblasts of the aortic media, and 
MMP-9 may be produced by inflammatory cells such as 
neutrophils and macrophages (Ruddy et al., 2008). The 
importance of MMP-9 in aneurysm development was 
further supported in a murine model, where aneurysm 
induction was inhibited in MMP-9 knockout mice (Longo 
et al., 2002).
Aneurysm is defined as a permanent localized dila-
tion of an artery whose diameter is at least 50 % greater 
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than the expected normal size. The vessel dilatation and 
weakening is caused by lysis of ECM, primarily of elas-
tin and collagen, in the aortic media and adventitia 
(Keeling et al., 2005). The majority of aortic aneurysms 
are localized in the abdominal aorta (Abraha et al., 2016). 
Aneurysms lead to death due to complications of aneu-
rysm expansion and rupture (Keisler and Carter, 2015). 
Aortoiliac occlusive disease (AOD), also referred to 
as Leriche syndrome, is the triad of claudication, impo-
tence and absent femoral pulses due to thrombotic oc-
clusion of the abdominal aorta just above the site of its 
bifurcation (Leriche and Morel, 1943). The complica-
tions in AOD include clot formation, development of 
acute ischaemia, and in severe disease it may result in 
distal limb amputation in cases of systemic disease 
(Wooten et al., 2014).
Studies show that abdominal aortic aneurysms (AAA) 
and AOD are related to underlying atherosclerotic dis-
ease (Golledge and Norman, 2010; Clair and Beach, 
2015). However, it is still unclear whether atherosclero-
sis precedes the AAA. As indicated in a recent study by 
Peshkova et al. (2016), several theories exist regarding 
the AAA aetiology. One is that atherosclerosis-driven 
changes in the aortic wall underlie AAA pathology, and 
the inflammatory mechanisms promoting atherosclero-
sis contribute to AAA. The second possibility is that dif-
ferent risk factors promote AAA and atherosclerosis 
separately, and they thus develop independently without 
greatly influencing each other. The third possibility is 
that the same risk factors promote both AAA and athero-
sclerosis via similar mechanisms, although additional 
factors are required for AAA induction. Thus, it is still 
unclear whether atherosclerosis can cause AAA devel-
opment, and whether inflammatory infiltrates and me-
diators represent a common denominator for atheroscle-
rosis and AAA development (Peshkova et al., 2016). 
Based on the premise that atherosclerosis stimulates 
AAA development, all patients with AAA are still con-
sidered to have significant atherosclerosis and should be 
considered for indicated therapy, as advised by AHA 
guidelines, in which AAA is considered an atheroscle-
rotic equivalent (Golledge and Norman, 2010; Gerhard-
Herman et al., 2016).
In atherosclerosis, MMPs play a role in neointima 
formation and SMC migration after vascular injury. Athe-
rosclerotic human vessels display increased levels of the 
members of the gelatinase subclass, MMP-2 and MMP-
9, as compared with healthy ones and destruction of 
elastic media was shown to depend on the increased ac-
tivity of elastolitic matrix metalloproteinases (MMPs) 
in the aortic wall of AAA and AOD (Azevedo et al., 2014). 
Thus, the objective of this study was to compare the 
histopathological (HP) findings in patients with AAA and 
AOD: immunohistochemical expression of MMP-2/
MMP-9 and their respective inhibitors, TIMP-2/TIMP-1, 
in all aortic layers, inflammatory cells (neutrophils and 
macrophages) and SMCs, aiming to identify the com-
mon underlying pathogenic mechanisms and to get fur-
ther insight into the biological processes of the disease 
development.
Material and Methods 
Patients
The study included 60 patients who underwent sur-
gery for AAA (30 cases) and AOD (30 cases) at the 
Department of Surgery, University Clinical Centre of 
the Republic of Srpska. The study was approved by the 
Ethics Committee of the Clinical Centre and the proto-
col was consistent with the World Medical Association 
Declaration of Helsinki. Patients with AAA and AOD 
operated as urgent surgical cases and those with previ-
ous surgery as well as patients with aneurysms at other 
localization were excluded from study. Clinical data 
were assessed by reviewing each patient’s medical his-
tory (Table 1). AAA and AOD were more frequent in 
males than females. Hypertension was present in almost 
all patients with AAA and AOD. The size of AAA was 
measured by angiography and it ranged from 3.5 to 
7.5 cm (median 5.47 cm).
Histological specimens
Infrarenal aortic wall specimens were taken during 
the surgery. The samples were immediately fixed in form-
aldehyde in the operating theatre, processed for histol-
ogy, and sections were cut and stained by the routine 
haematoxylin-eosin (HE) method and analysed by light 
microscopy to examine the following parameters: cho-
lesterol crystals, calcification, inflammatory infiltrate 
(0 – negative, 1 – slight, 2 – moderate, and 3 – severe), 
extracellular lipids, thrombosis and ulceration (0 – no, 
1 – yes). 
Immunohistochemistry 
Immunohistochemical analysis of MMP-2, MMP-9, 
TIMP-1, and TIMP-2 was performed in 5 μm sections 
prepared from paraffin-embedded human AAA walls 
and abdominal aorta with AOD. Specimens were pro-
cessed as follows: for retrieval of antigens, a high-tem-
perature technique was used (histological slides were 
placed in 10 mmol/l citrate buffer, pH 6.0, and heated at 
Table 1. Clinical data of the patients with AAA and AOD
Group Number 
of patients
Age (years)
Min/Max/Med
Sex
(F/M)
Chronical course
Asymptomatic/ Symptomatic
Diabetes 
Yes/No
Hypertension
Yes/No
AAA 30 46/80/67.77 4/26 15/15 4/26 25/5
AOD 30 49/82/65.80 10/20 0/30 4/26 24/6
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96 °C for 20 min in a PT module). Primary monoclonal 
antibodies for MMP-2 (mouse monoclonal antihuman 
MMP-2 antibody, A-Gel VC2), TIMP-1 (mouse mono-
clonal antihuman TIMP-1 antibody, 102D1), TIMP-2 
(mouse monoclonal antihuman TIMP-2 antibody, 3A4), 
and rabbit polyclonal antihuman MMP-9 antibody for 
MMP-9 (all by Lab Vision-USA, Fermont, CA) were 
used. For MMP-9, TIMP-1 and TIMP-2, pre-diluted 
(ready-to-use) antibodies were used, while anti-MMP-2 
antibody was used at 1 : 100 dilution. All slides were 
incubated in the primary antibody overnight at 4 °C, 
followed by incubation with secondary antibodies 
(UltraVision LP Detection System: HRP polymer/DAB 
Plus Chromogen; LabVision-USA) for 25 min at room 
temperature. The binding reaction was detected using 
3,3’- diaminobenzidine.
The results were semi-quantitatively evaluated by ob-
serving the presence of yellowish-brown particles with-
in the cytoplasm. For the assessment of stained cells 
(lymphocytes, macrophages and SMCs), 100 randomly 
chosen cells were observed for staining. The results of 
immunohistochemical staining were scored as 0 (< 10 % 
of the cells), 1 (11 %–25 % of the cells), 2 (26 %– 50% 
of the cells) and 3, when > 50 % of the cells were stained. 
For analyses, the cases with scores 2 and 3 were consid-
ered to have elevated MMP and TIMP expression in the 
observed cells. The expression of MMPs and their tissue 
inhibitors was graded separately for the intima, media 
and adventitia, as well as for the inflammatory cells 
(lymphocytes and macrophages) and SMCs.
Statistics
Statistical analyses were performed with SPSS 23.0 
for Windows (SPSS Inc., Chicago, IL). To compare the 
frequency score distribution for HP findings, Fisher’s 
exact test for 2 × 2 contingency tables or χ2 test for 4 × 4 
tables were used. To compare the MMP/TIMP expres-
sion scores in aortic layers, the rank-based nonparamet-
ric Kruskal-Wallis H test (H is tested as a χ2 variable), 
appropriate for non-normal distributed data sets, fol-
lowed by Dunn’s multiple comparison test was used. 
The differences in the expression score frequencies be-
tween SMCs and each inflammatory cell type separately 
were tested by the χ2 test. The P values < 0.05 were con-
sidered significant.
Results
Histopathology 
The semi-quantitative grading in AAA and AOD 
specimens (Table 2) showed that thrombosis and ulcera-
tion were more frequent in AOD than in AAA (P = 0.007 
and P = 0.03, respectively), while accumulation of lipids 
in foam cells was not statistically different (P = 0.612) 
(Fisher’s exact test). There was no significant difference 
in accumulated cholesterol crystals (P = 0.170), calcifi-
cation (P = 0.189), or degree of inflammatory infiltrate 
(P = 0.635) (χ2 test) between AAA and AOD specimens. 
MMP and TIMP expression in AAA
Table 3 and Fig. 1 present data on the scores of MMP 
and TIMP expression in the aortic layers, inflammatory 
cells and SMCs in the specimens from AAA patients. 
A significant difference in the expression scores of the 
examined parameters was found in each aortic layer 
(media, H = 17.03, P = 0.0007; intima, H = 19.61, P = 
0.0002; adventitia, H = 25.54, P < 0.0001, Kruskal-
Wallis test).
Dunn’s post hoc test revealed a significant difference 
(P < 0.05) in the expression scores between MMP-2 and 
MMP-9 in the media, intima and adventitia. An elevated 
MMP-9 level was observed in 46.67 % (media), 63.33 % 
(intima) and 50 % (adventitia) of patients. There was 
also a significant difference in MMP-9 vs. TIMP-1 ex-
pression in the media and adventitia (P < 0.05). Negative 
and low TIMP-1 expression was observed in 80 % (me-
dia) and 93.33 % (adventitia) of patients (Table 3A).
Analysis of the expression scores between SMCs and 
inflammatory cells (χ2 test) revealed a significant differ-
ence in the MMP-9 (P = 0.008), TIMP-1 (P = 0.0145) 
and TIMP-2 (P < 0.0001) level between SMCs/lympho-
cytes; and in the TIMP-1 (P < 0.0001) and TIMP-2 (P = 
0.0003) level between SMCs/macrophages. 
Elevated MMP-9 expression was noticed in 60 % of 
SMCs (18 patients) and in 66.67 % of macrophages 
(20 patients), while 30 % of lymphocytes had high 
MMP-9 expression. Enhanced expression of TIMPs was 
observed in 50 % and 86.6 % (TIMP-1), and in 73.3 % 
and 60 % (TIMP-2) of lymphocytes and macrophages, 
respectively, Table 3B. 
Table 2. Histopathological analysis in AAA and AOD
Cholesterol Calcification Inflammatory 
infiltrate
Lipids Thrombosis Ulceration
Groups/Scores  0 1 2 3  0 1 2 3  0 1 2 3  0 1  0 1  0 1
AAA (N)  4 12 2 12  1 8 12 11  1 18 9 2  29 1  29 1  29 1
AOD (N)  7 13 5 5  1 11 4 14  2 21 5 2  27 3  13 17  11 19
χ2 P value 0.170 0.189 0. 635 0.612 0.007 0.030
Haematoxylin-eosin staining score: cholesterol crystals, calcification, inflammatory infiltrate (0 – negative, 1 – slight, 2 – moderate, 
3 – severe); extracellular lipids, thrombosis, ulceration (0 – no, 1 – yes); (N) – number of patients
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Table 3. Immunohistochemical staining scores of MMPs and TIMPs in AAA patients 
A)
MMP-2 MMP-9 TIMP-1 TIMP-2 P value
(Kruskal-Wallis)
Groups/Scores  0 1 2 3  0 1 2 3  0 1 2 3  0 1 2 3
media (N)  14 15 1 0  4 12 8 6*  14 10 3 3#  10 15 3 2 0.0007
intima (N)  4 12 12 2  3 8 4 15*  1 1 11 17  1 10 11 8 0.0002
adventitia (N)  18 10 2 0  5 10 6 9*  16 12 2 0#  14 14 2 0 < 0.0001
Dunns’ test (P < 0.05): * MMP-2 vs. MMP-9; # MMP-9 vs. TIMP-1
B)
SMCs (N)  10 14 5 1  2 10 5 13  10 14 6 0  9 16 5 0
lymphocytes (N)  10 14 6 0  4 16 10 0  9 6 8 7  1 7 15 7
χ2 P value 0.7700 0.0008 0.0145 < 0.0001
macrophages (N)  7 10 11 2  1 9 7 13  0 4 13 13  0 12 11 7
χ2 P value 0.2860 0.8687 < 0.0001 0.0003
χ2 P value (χ2 test): SMCs vs. lymphocytes; SMCs vs. macrophages
Expression scores: 0 (< 10% of the cells), 1 (11 %–25 % of the cells), 2 (26 %–50 % of the cells), 3 (> 50% of the cells); (N) – number 
of patients
Fig. 1. Expression of MMPs and TIMPs in AAA samples. A) immunostaining of MMP-2 expression in inflammatory cells 
and SMCs (original magnification ×20), B) immunostaining of MMP-9 expression in inflammatory cells (original mag-
nification ×20), C) immunostaining of MMP-9 expression in SMCs (original magnification ×10), D) immunostaining of 
TIMP-1 expression in inflammatory cells and SMCs (original magnification ×10)
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Table 4. Immunohistochemical staining scores of MMPs and TIMPs in AOD patients 
A)
MMP-2 MMP-9 TIMP-1 TIMP-2 P value 
(Kruskal-Wallis)
Groups/scores  0 1 2 3  0 1 2 3  0 1 2 3  0 1 2 3
media (N)  16 9 4 1  5 10 4 11*  6 18 5 1#  11 16 3 0 0.0004
intima (N)  10 8 12 0  8 6 10 6  2 6 14 8  2 12 12 4 0.0077
adventitia (N)  21 8 1 0  10 10 4 6*  24 5 0 1  18 12 0 0 0.0002
Dunns’ test (p < 0.05): * MMP-2 vs. MMP-9; # MMP-9 vs. TIMP-1
B)
SMCs (N)  15 10 4 1  4 11 2 13  7 20 3 0  12 18 0 0
lymphocytes (N)  17 10 3 0  8 10 7 5  11 14 4 1  6 18 5 1
χ2 P-value 0.7368 0.0520 0.3779 0.0460
macrophages (N)  10 11 9 0  6 8 7 9  2 11 11 6  3 11 13 3
χ2 P-value 0.3971 0.2234 0.0012 0.0001
χ2 P-value (χ2 test): SMCs vs. lymphocytes; SMCs vs. macrophages
Expression scores: 0 (< 10% of the cells), 1 (11 %–25 % of the cells), 2 (26 %–50 % of the cells), 3 (> 50 % of the cells); (N) – number 
of patients
Fig. 2. Expression of MMPs and TIMPs in AOD samples. A) immunostaining of MMP-2 expression in inflammatory cells 
(original magnification ×10), B) immunostaining of MMP-9 expression in inflammatory cells (original magnification 
×10), C) immunostaining of MMP-9 expression in SMCs (original magnification ×10), D) immunostaining of TIMP-1 
expression in inflammatory cells and SMCs (original magnification ×20)
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MMP and TIMP expression in AOD 
Table 4 and Fig. 2 present data on the scores of MMP 
and TIMP expression in the aortic layers, inflammatory 
cells and SMCs in the specimens from AOD patients. As 
in AAA patients, a significant difference in the expres-
sion scores was found in each aortic layer (media, H = 
18.25, P = 0.0004; intima, H = 11.91, P = 0.0077; adven-
titia, H = 19.92, P = 0.0002, Kruskal-Wallis test).
Dunn’s post hoc test revealed a difference in the ex-
pression scores between MMP-2 and MMP-9 in the me-
dia and adventitia (P < 0.05). Higher MMP-9 expression 
scores were found in 50 % (15 patients) and 53.33 % 
(16 patients) in the media and adventitia, respectively. 
There was also a difference in MMP-9 vs. TIMP-1 ex-
pression (P < 0.05) in the media, in which negative and 
low TIMP-1 expression was found in 80 % of patients 
(Table 4A).
Analysis of the expression scores between SMCs and 
inflammatory cells (χ2 test) showed a borderline signifi-
cant difference in MMP-9 (P = 0.052) and TIMP-2 (P = 
0.046) between SMCs/lymphocytes; and in TIMP-1 
(P = 0.0012) and TIMP-2 (P = 0.0001) between SMCs/
macrophages. 
Elevated MMP-9 expression was noticed in 50 % of 
SMCs (15 patients) and in 53.33 % of macrophages 
(16 patients), while 40 % of lymphocytes had high 
MMP-9 expression. Enhanced expression of TIMP-1 
and TIMP-2 was observed in macrophages of 56.66 % 
and 53.33 % patients, respectively. Only 20 % of pa-
tients had elevated TIMP-2 expression in lymphocytes, 
Table 4B.
Discussion
Arterial remodelling is now being recognized as an 
important determinant in vascular pathology. Arterial 
restructuring requires breakdown of the extracellular 
matrix, which is supported by non-specific up-regula-
tion of the MMPs (Pasterkamp et al., 2000). Of the 
MMPs, MMP-2 and MMP-9 are considered to be cen-
tral to the vascular remodelling processes (Chase and 
Newby, 2003). In this study, we compared the expres-
sion of MMP-2, MMP-9 and their inhibitors TIMP-2 
and TIMP-1, respectively, in the aortic wall, SMCs and 
inflammatory cells of patients with dilatative and occlu-
sive pathology. All specimens taken from AAA and 
AOD patients had various advanced atherosclerotic le-
sions, and the findings point to certain similarities in 
MMP and TIMP expression in both pathologic condi-
tions. 
In the analysis of MMP/TIMP expression in aortic 
layers, we noticed higher MMP-9 expression in the 
whole aortic wall of AAA patients, while in AOD sub-
jects, the MMP-9 expression was elevated in the media 
and adventitia. Previously, similar quantities of MMP-9 
were reported in both aneurysmal and occlusive aortic 
tissue (Crowther et al., 2000). The elevation of MMP-9 
expression was mainly followed by lower TIMP-1 ex-
pression scores. Different MMP and TIMP expression in 
the aortic wall layers observed in this study is in accord-
ance with previous data (Petersen et al., 2000; Liapis 
and Paraskevas, 2003). 
However, we noticed lower MMP-2 expression in 
the aortic layers in both diagnoses when compared to 
MMP-9. It is known that MMP-2 is synthesized by the 
SMCs of the intima and media wall as well as by adven-
titial fibroblasts (Newby, 2005). MMP-2 derived from 
mesenchymal lineage cells may play a prominent role in 
the initiation of ECM changes that cause aneurysmal 
dilatation. Evidence suggests that MMP-2 was the dom-
inant elastolytic enzyme in the wall of small early aneu-
rysms, with MMP-9 becoming most prominent as the 
inflammatory infiltrate increased in density. It was dem-
onstrated that AAAs smaller than 5.5 cm had greater 
MMP-2 activity than larger aneurysms, indicating that 
early AAA growth is directed by MMP-2 (Freestone et 
al., 1995; Saratzis and Bown, 2014). Our results of high-
er MMP-9 and lower MMP-2 expression may also be in 
accordance with these findings, since our specimens 
consisted of AAA that ranged from 3.5 to 7.5 cm.
Regarding the TIMP expression, McMillan et al. 
(1995) found that in AAA and AOD specimens, TIMP-1 
and TIMP-2 were localized in the adventitia. In our 
study, we observed hihger expression of both TIMPs in 
the intima. The different MMP and TIMP expression in 
the aortic wall layers observed in this study is in accord-
ance with previous data that indicated involvement of 
MMPs/TIMPs in AAA and AOD in aneurysmal and 
plaque instability (Petersen et al., 2000; Liapis and 
Paraskevas, 2003). However, the clear ratio has not been 
fully elucidated and data are still conflicting. It is known 
that extensive remodelling of the aortic wall in AAA and 
AOD involves synthesis and degradation of structural 
matrix proteins, in which the biomechanical properties 
of the vessel largely depend on the collagen proportion. 
Such compensatory repair process has been shown in 
human AAA and AOD and in animal models (Defawe et 
al., 2003).
Multiple cell types, including SMCs and inflamma-
tory cells, populate the wall of an AAA and AOD. Each 
of these cell types is capable of producing proteases. In 
previous studies, inflammatory cells have been impli-
cated as the major source of MMPs in the aneurysm de-
velopment (Freestone et al., 1995; LeMaire et al., 2005). 
Phenotypic changes in SMCs and transition to the syn-
thetic type from the contractile one has been associated 
with MMP expression and activity, since SMCs produce 
MMP-1, -2, -3, -7, -9, and -14 (Galis and Khatri, 2002; 
Beamish et al., 2010). According to our results, MMP-9 
appears to be the predominant metalloproteinase ex-
pressed in AAA and in syndrome Leriche, since we re-
corded elevated expression of MMP-9 in SMCs and 
macrophages.
Consistent with these results is the fact that during the 
formation of the aneurysm, extensive infiltration of in-
flammatory cells (macrophages and lymphocytes) is ob-
served in all aortic layers (Reeps et al., 2014). Mesen-
N. Vasic et al.
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chymal cells do not express MMP-9 under normal 
conditions, but SMC production can be induced by a 
proinflammatory milieu, as occurs in AAA tissue (Gurjar 
et al., 2001). Conversely, macrophages produce rela-
tively large amounts of MMP-9. The findings obtained 
on an animal model are consistent with histologic stud-
ies showing macrophages to be the primary source of 
MMP-9 in human AAA tissue (Longo et al., 2002). It 
was also reported that occlusive atherosclerotic lesions 
had higher MMP-9 expression (Orbe et al., 2003).
Many lines of evidence have suggested that high lev-
els of MMP-2 and MMP-9 may contribute to the aneu-
rysm formation (Ailawadi et al., 2009) and progression 
of AAA toward rupture (Petersen et al., 2000). The in-
creased release of MMP-9 from inflammatory cells in 
the abdominal aorta causes continued growth of AAA 
(Theruvath et al., 2012) and failure of vascular grafts 
(Johnson et al., 2001), where MMP-2 and MMP-9 over-
expression was noticed at neointimal lesions after expo-
sure to arterial pressure (Chung et al., 2005).
In our study, elevated staining of TIMP-1 and TIMP-2 
was predominantly observed in lymphocytes and mac-
rophages of AAA patients. Originally, TIMPs were 
thought to function exclusively as endogenous inhibi-
tors of MMP activity. However, recent reports have 
shown that TIMPs have a much broader spectrum of 
targets than originally believed. Mounting evidence 
points towards a function of TIMPs in a variety of bio-
logical processes such as apoptosis, cell survival, growth, 
migration, differentiation, angiogenesis, inflammation 
and ECM remodelling, and may play a central role in 
the process of cardiovascular remodelling (Vanhoutte 
and Heymans, 2010).
TIMP-1 levels were found to be unchanged or elevat-
ed in human atherosclerotic plaques, whereas TIMP-2 
was also abundant (Newby, 2008). Overall, human ad-
vanced atherosclerotic lesions showed overexpression 
of all MMPs and TIMP-1, which appeared most abun-
dant in lipid- and macrophage-rich atheromatous com-
pared with fibrous (SMC-rich) plaques (Orbe et al., 
2003). Lesauskaite et al. (2006) demonstrated that in the 
wall of AAA, TIMP-1 was expressed more by inflam-
matory cells than by SMCs, whereas expression of 
TIMP-2 did not differ significantly between SMCs and 
inflammatory cells. 
Despite similarities underlying the development of 
AAA and AOD, including increased MMP and TIMP 
expression, it is still unclear why some patients develop 
aneurysm and some occlusive arterial disease. It is pos-
sible that differences in the expression pattern of MMPs 
and TIMPs may determine whether atherosclerotic aorta 
will develop dilatative or stenosing disease.
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